Blog
48 Articles
Treating Cancer By Mutation, Not by Tumor Location
Dr. Conan Kinsey outlines the latest basket trials, which focus on tumor mutation, not the location of the cancer.
The Bottom Line Is Optimism
For Gary Fong, his optimism about survival is an important part of his treatment along with surgery, chemotherapy, and immunotherapy.
Early Diagnosis Is Important
Jami Curry knew her family history included breast and pancreatic cancer, so she was alert to any health changes.
Extensive Family History and Genetic Testing Leads to Early Detection
Sidney Levinson and his doctor were aware of his BRCA1/2 mutations so when an MRI was recommended for screening, Sidney did it.
Genetic Testing Guided My Treatment Plan
Ryan Dwars already knew there was pancreatic cancer in his family so when he was diagnosed he asked for genetic testing right away.
Don’t Let Doctors Tell You Nothing’s Wrong
After a long road to diagnosis Brandon Stone learned he has a BRCA2 genetic mutation that impacts his treatment.
Genetic Testing Changed My Chemo Protocol
Greg Jacobson’s family has an extensive history of cancer. After a pancreatic cancer diagnosis, genetic testing found the mutation for Lynch syndrome.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
Changing Course Midstream
Barbara Green wasn’t happy with her doctors, so she took the advice of her support group, was an advocate for herself, and changed doctors.
Urinary Tract Scans Lead to My Diagnosis
Ellen Robbins has the BRCA2 mutation, and that allowed her to participate in a clinical trial for her pancreatic cancer.
New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
KRYSTAL-1 Trial Shows Promising Activity in Pancreas and Other GI Cancers
Dr. Tanios Bekaii-Saab reports promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer.
Cherishing the Simple Things
Elizabeth O’Connor has a PALB2 genetic mutation so her stage IV pancreatic cancer has responded to immunotherapy.
Testing an Approved Drug for a Specific Mutation
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.